Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06034691
Other study ID # LY2023-113-A
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 10, 2023
Est. completion date October 1, 2024

Study information

Verified date September 2023
Source RenJi Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Autologous arteriovenous fistula (AVF) is the preferred vascular pathway type for maintenance hemodialysis (MHD) patients. The K/DOQI guidelines suggest that the use of percutaneous transluminal angioplasty (PTA) as the primary treatment for AVF stenosis is reasonable. However, the durability of PTA is limited. In order to reduce the risk of dysfunction recurrence after the intervention, there have been reports in recent years that drug-coated balloons (DCB) are used in the treatment of vascular stenosis in hemodialysis. Multiple factors have limited the efficacy of DCB. Previous studies on the related factors of hemodialysis access stenosis showed that Dyslipidemia was significantly related to the short initial patency rate, and Dyslipidemia was an important predictor of secondary patency loss. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new type of lipid-lowering drug that can prevent vascular calcification. Previous studies have shown that PCSK9 inhibitors have good lipid-lowering effects in both MHD patients and nondialysis patients, and the use of PSK9 inhibitors at the same dose as nondialysis patients is safe in MHD patients. There are currently few studies on the use of paclitaxel-releasing balloon dilation combined with PCSK9 inhibitors to improve autologous internal fistula. Therefore, the investigators applied a prospective, randomized, and controlled study method to preliminarily explore the effect of paclitaxel releasing balloon combined with PCSK9 inhibitor on improving the postoperative patency rate of AVF and the safety of the combined application.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 1, 2024
Est. primary completion date September 6, 2024
Accepts healthy volunteers No
Gender All
Age group 17 Years to 76 Years
Eligibility Inclusion Criteria: 1. Agree to join this study and sign an informed consent form 2. Age = 18 years old and = 75 years old, regardless of gender 3. Maintenance hemodialysis patients using autologous arteriovenous fistula (AVF), with a dialysis frequency of three times a week 4. AVF venous stenosis: The local stenosis rate exceeds 50% of the normal diameter of nearby blood vessels and is accompanied by at least one of the following conditions: 1. The natural blood flow of the internal fistula is less than 500ml/min or has decreased by more than 25% compared to the previous examination result 2. Unable to meet the required blood flow for dialysis prescription (blood flow<200ml/min, and cannot be corrected after adjusting the puncture needle position) 3. Decreased arterial pressure or increased venous pressure during dialysis (monitoring arterial pressure<-120mmHg for more than 2 consecutive times or monitoring venous pressure>120mmHg while maintaining 200ml/min blood flow) 4. Difficulty in puncture: A qualified nurse who has difficulty puncturing for 3 consecutive days of hemodialysis (blood can only be drawn out after more than two punctures) 5. Decreased dialysis adequacy [arteriovenous fistula recirculation rate (RA)>10%, or an increase of more than 25% compared to the previous examination result] [RA=(SA-A)/(SA-V) * 100, dialysis to 1 hour: SA=blood flow adjusted to 20ml/min, ultrafiltration and dialysate flow stopped, after 2 minutes, artery Blood urea nitrogen concentration A=artery Blood urea nitrogen concentration V=vein Blood urea nitrogen concentration] 6. Abnormal signs of fistula. 5. Patients with primary Hypercholesterolemia [LDL-C = 130 mg/dl (= 3.4 mmol/L), and/or non-HDL-C= 160 mg/dl (= 4.1 mmol/L)] or combine cardiovascular disease or assess patients with a high risk of cardiovascular disease Exclusion Criteria: 1. MHD with AVG 2. Breastfeeding or Pregnant Women 3. Patients with central venous reflux obstruction 4. Patients with AVF feeding artery disease 5. Patients with severe Hypotension (systolic blood pressure<90mmHg or diastolic blood pressure<60mmHg, at least three times within one month before signing the informed consent) 6. Left ventricular Ejection fraction less than 30% or hemodynamic instability 7. Patients receiving immunotherapy or suspected/confirmed Vasculitis 8. Patients with coagulation dysfunction or a history of Thrombocytopenic purpura 9. Patients with vascular access infections or systemic active infections 10. Patients who are known to be allergic to PCSK9 inhibitors or paclitaxel 11. Patient's life expectancy is less than 12 months 12. Patients who are planning kidney transplantation or switching to Peritoneal dialysis 13. Patients participating in other intervention studies 14. The researcher judged that the subject's condition was not suitable for participation in this study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
pcsk9 inhibitor
The treatment group received postoperative use of 140 mg of Ribavirin, administered every two weeks, with 140 mg administered subcutaneously for a total of 48 weeks. There was no additional intervention with lipid-lowering drugs in the control group.

Locations

Country Name City State
China Yuanyuan Xie Shanghai Pudong

Sponsors (1)

Lead Sponsor Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Value of vessel diameter ultrasonic measurement 24 week, 48 week
Primary Value of volume of blood flow ultrasonic measurement 24 week, 48 week
Primary Value of peak systolic velocity ratio(PSVR) ultrasonic measurement 24 week, 48 week
Primary Incidence of Re intervention of fistula Event recording 48 week
Secondary Endometrium Ultrasonic measurement of changes in thickness of vascular intima , expressed in millimeters 24 week, 48 week
Secondary RA Arteriovenous fistula recirculation rate 24 week, 48 week
Secondary BTM Blood temperature monitoring, testing of specific modules of the hemodialysis machine. Expressed as a percentage. 24 week, 48 week
Secondary Adequacy of dialysis spKT/V 24 week, 48 week
Secondary Blood routine Concentration of hemoglobin, white blood cell count, platelet 12 week, 24 week, 48 week
Secondary liver function Concentration of GPT, GOT 12 week, 24 week, 48 week
Secondary Concentration of blood sugar 12 week, 24 week, 48 week
Secondary Concentration of CRP 12 week, 24 week, 48 week
Secondary blood lipids Concentration of cholesterol, triglyceride, LDL-c, HDL 12 week, 24 week, 48 week
See also
  Status Clinical Trial Phase
Completed NCT03952819 - The Effects of Hemodialysis on Serum Sclerostin Levels
Active, not recruiting NCT04054128 - Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients Phase 4
Active, not recruiting NCT04376567 - Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas N/A
Completed NCT03627884 - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Phase 4
Recruiting NCT06001827 - SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study N/A
Recruiting NCT04285073 - Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease. N/A
Recruiting NCT05906550 - Flow Dysfunction of Hemodialysis Vascular Access N/A
Not yet recruiting NCT04098159 - Role of Regular Surveillance on Maintenance of Patency of an Arteriovenous Access N/A
Terminated NCT05228132 - The Pristine Post-Market Study N/A
Recruiting NCT03365089 - Collateral Ligation in Failing Fistulas N/A
Recruiting NCT04489849 - Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access Phase 4
Recruiting NCT03140345 - Integrative HD Vascular Access Assessment N/A
Enrolling by invitation NCT04381754 - Use of Implanting the Biotronik Passeo-18 Lux Drug Coated Balloon to Treat Failing Haemodialysis Arteriovenous Fistulas and Grafts.
Completed NCT03988270 - Prefistula Forearm Exercise in Pts Requiring Chronic HD Therapy N/A
Recruiting NCT04502160 - The Northern Ireland Haemodialysis Vascular Access Database
Active, not recruiting NCT05418816 - SelfWrap-Assisted Arteriovenous Fistulas N/A
Completed NCT04263116 - Balloon-Assisted Maturation of Autogenous Arteriovenous Fistulae N/A
Completed NCT05081648 - Must Cannulation Technique of Vascular Access in Patients Undergoing Haemodialysis: Contributions for a Safe Nursing Intervention N/A
Recruiting NCT06454396 - Effectiveness and Health Economics of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure
Not yet recruiting NCT05096416 - Three-dimensional (3D) Printed Hemodialysis Vascular Model N/A